Selectively targeting YTHDF2 in tumor-associated macrophages (TAMs) using a Toll-like receptor 9 agonist-conjugated small interfering RNA reprogrammed TAMs toward an antitumoral phenotype, restrained tumor growth, and enhanced the efficacy of PD-L1 antibody therapy.
[Nature Immunology]